pentetic acid
on as chelating agents in cosmetics. Pentasodium Pentetate is readily soluble in water, but the corresponding free acid is not. Pentasodium Pentetate is used in almost 400 cosmetic products over a wide range of product categories, although it is mostly used in hair dyes and colors at use concentrations of 0.1% to 1.0%. Pentetic Acid and Pentasodium Pentetate inactivate metallic ions, such as calcium and magnesium, to maintain stability and appearance of cosmetic products. The inactivation of other metallic ions such as iron or copper also helps to prevent the oxidative deterioration of cosmetics and personal care products. — NCATS
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 1996 (NCT00019227)
Timeline
1990s
- Jan 1, 1996
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
SMILES
OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O- Mol. weight
- 393.3465 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaPentetic acid ↗
- NCATS7A314HQM0I ↗
- ChEMBLCHEMBL780 ↗
- ChEMBLCHEMBL2096656 ↗
Also known as
- an-dtpa
- an-dtpa
- calcium dtpa
- detapac
- detarex
- diethylenetriaminepentaacetic acid
- dtpa
- dtpa
- in-111 dtpa
- in111-dtpa
- pentetate
- pentetate
- pentetic acid
- pentetic acid
- pentetic acid
- pentetic acid
- pentetic acid
- pentetic acid
- pentetic acid calcium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05359835 | Early Phase 1 (Phase 1) | Dec 15, 2022 | Stanford University |
| NCT06116253 | N/A | Dec 1, 2022 | National Institutes of Health (NIH), New York University |
| NCT02947126 | N/A | Nov 1, 2016 | National Heart, Lung, and Blood Institute (NHLBI), University of Pittsburgh |
| NCT00477503 | Phase 1 | May 1, 2007 | University of Texas at Houston |
| NCT00019227 | Phase 1/Phase 2 (Phase 2) | Oct 1, 1996 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institutes of Health (NIH) | Government | 2 | 0 | 2 | 1996 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 1996 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2016 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2007 |